X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

The US Has Prolonged The COVID-19 Public Health Emergency

Content Team by Content Team
18th July 2022
in News
T2 Biosystems T2SARS-CoV-2 Panel Detects Omicron Subvariants

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The COVID-19 public health emergency was prolonged by the Biden administration on July 15th for a further three months. The declaration was officially renewed by Xavier Becerra, Secretary of the US Department of Health and Human Services, and was extended through October 13, 2022.

The newest extension of the emergency declaration, which has been in effect since January 2020, comes as the Omicron branch BA.5, the most contagious strain to date, is making inroads in the US. The number of COVID-19 hospitalizations and fatalities is at its highest level in months, despite the fact that daily case rates are substantially undercounted.

More than half of the population of the US resides in counties with a high COVID-19 Community Level, according to data released this week by the US Centers for Disease Control and Prevention, in which the medical system is at risk of becoming overwhelmed and mandatory indoor masking is advised.

A Biden administration source said that the Public Health Emergency proclamation continues to provide them with the resources and powers necessary to respond to the highly communicable COVID-19 subvariants that are now spreading around the country. The PHE gives hospitals crucial flexibility and capacity to better care for patients, especially if they were to witness a dramatic spike in admissions in the coming weeks.

Hospitalizations in the US are expected to increase over the course of the upcoming month, according to ensemble estimates from the CDC that were published this week ending July 16th. For the first time in a few weeks, the forecasts indicated a surge in hospitalizations rather than a continuing constant trend.

The official stated that without the PHE, they would be constrained in their ability to deliver broad and equitable access to life-saving medications through the Test to Treat programme, for example, which depends on flexibility for telemedicine and operations.

The declaration of a public health emergency entitles many Americans to free COVID-19 testing, medical care, and vaccinations. Depending on whether they have Medicare, Medicaid, or Private insurance after it expires, they may have to pay out-of-pocket expenses. While state Medicaid programmes would decide whether to keep covering vaccinations for their participants, those eligible for Medicaid and private insurance would generally continue to receive free immunizations.

Additionally, Medicare has loosened its telemedicine regulations so that a greater number of enrollees can use these services during the declaration. Enrollees can perform visits at home rather than travel to a medical institution, and they can access a greater range of treatments through telehealth. Telehealth services are no longer only available to those who live in remote areas. After the crisis ends, most recipients’ access to these flexibility options will terminate.

And in exchange for obtaining more generous federal matching money, states are not forcibly removing residents from Medicaid during the declaration. Following the conclusion of the emergency, up to 14 million Americans might lose their Medicaid coverage, according to different forecasts made by Kaiser and the Urban Institute. The proclamation has also resulted in many low-income families obtaining increased food stamp benefits, even though several states have concluded their respective public health emergencies and ceased the increased allotments.

Testing, treatments, and immunizations may be used in an emergency under a separate emergency declaration. The US Department of Health and Human Services secretary will decide when it will cease. HHS will determine when it ends, and the organisation has agreed to give at least 60 days’ notice before any changes.

Previous Post

The Fourth COVID-19 Vaccine Reduces Senior Mortality By 72%

Next Post

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In